J Bryant1, J Picot, L Baxter, G Levitt, I Sullivan, A Clegg. 1. Southampton Health Technology Assessments Centre, Wessex Institute for Health Research and Development, Mailpoint 728, Boldrewood, University of Southampton, Southampton SO16 7PX, United Kingdom. J.S.Bryant@soton.ac.uk
Abstract
AIM: To evaluate the effectiveness of cardiac markers to quantify anthracycline-induced cardiotoxicity in children with cancer. METHODS: Systematic review using a priori methods. RESULTS: Seven studies, all with methodological limitations, were identified. One RCT suggests that cardiac troponin can be used to assess the effectiveness of the cardio-protective agent dexrazoxane. Cohort studies suggest that atrial natriuretic peptide and brain (B-type) natriuretic peptide are elevated in some subgroups of patients compared with healthy children; NT-pro-BNP levels are significantly elevated in children with cardiac dysfunction compared with those without; serum lipid peroxide is higher in children who have received doxorubicin compared with children not receiving doxorubicin; there are no differences in carnitine levels between children treated with doxorubicin and a healthy control group. CONCLUSIONS: The limited evidence makes conclusions difficult. Research is needed to fill this important evidence gap and link short-term changes in cardiac markers to longer-term cardiac damage.
AIM: To evaluate the effectiveness of cardiac markers to quantify anthracycline-induced cardiotoxicity in children with cancer. METHODS: Systematic review using a priori methods. RESULTS: Seven studies, all with methodological limitations, were identified. One RCT suggests that cardiac troponin can be used to assess the effectiveness of the cardio-protective agent dexrazoxane. Cohort studies suggest that atrial natriuretic peptide and brain (B-type) natriuretic peptide are elevated in some subgroups of patients compared with healthy children; NT-pro-BNP levels are significantly elevated in children with cardiac dysfunction compared with those without; serum lipidperoxide is higher in children who have received doxorubicin compared with children not receiving doxorubicin; there are no differences in carnitine levels between children treated with doxorubicin and a healthy control group. CONCLUSIONS: The limited evidence makes conclusions difficult. Research is needed to fill this important evidence gap and link short-term changes in cardiac markers to longer-term cardiac damage.
Authors: Frederik J F Broeyer; Susanne Osanto; Jun Suzuki; Felix de Jongh; Henk van Slooten; Bea C Tanis; Tobias Bruning; Jeroen J Bax; Henk J Ritsema van Eck; Marieke L de Kam; Adam F Cohen; Yutaka Mituzhima; Jacobus Burggraaf Journal: Br J Clin Pharmacol Date: 2014-11 Impact factor: 4.335
Authors: Anindita Das; David Durrant; Clint Mitchell; Eric Mayton; Nicholas N Hoke; Fadi N Salloum; Margaret A Park; Ian Qureshi; Ray Lee; Paul Dent; Rakesh C Kukreja Journal: Proc Natl Acad Sci U S A Date: 2010-09-30 Impact factor: 11.205
Authors: R Altena; E C de Haas; J Nuver; C A J Brouwer; M P van den Berg; A J Smit; A Postma; D Th Sleijfer; J A Gietema Journal: Br J Cancer Date: 2009-05-19 Impact factor: 7.640
Authors: Berthe M P Aleman; Elizabeth C Moser; Janine Nuver; Thomas M Suter; Maja V Maraldo; Lena Specht; Conny Vrieling; Sarah C Darby Journal: EJC Suppl Date: 2014-05-29